The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
Open accessAbstract
Early dissemination, metastasis and therapy resistance are central hallmarks of aggressive cancer types and the leading cause of cancer-associated deaths. The EMT-inducing transcriptional repressor ZEB1 is a crucial stimulator of these processes, particularly by coupling the activation of cellular motility with stemness and survival properties. ZEB1 expression is associated with aggressive behaviour in many tumour types, but the potent effects cannot be solely explained by its proven function as a transcriptional repressor of epithelial genes. Here we describe a direct interaction of ZEB1 with the Hippo pathway effector YAP, but notably not with its paralogue TAZ. In consequence, ZEB1 switches its function to a transcriptional co-activator of a ‘common ZEB1/YAP target gene set’, thereby linking two pathways with similar cancer promoting effects. This gene set is a predictor of poor survival, therapy resistance and increased metastatic risk in breast cancer, indicating the clinical relevance of our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Cited by
YAP/TAZ upstream signals and downstream responses
Totaro, A., Panciera, T., & Piccolo, S. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0142-z · Cited by 1,086
Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis
Lu, W., & Kang, Y. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.010 · Cited by 1,030
Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3513 · Cited by 975
Self-citationDynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 761
Self-citationPhenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance
Gupta, P. B., Pastushenko, I., Skibinski, A., Blanpain, C., & Kuperwasser, C. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.011 · Cited by 598
Context-dependent EMT programs in cancer metastasis
Aiello, N. M., & Kang, Y. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181827 · Cited by 584
Non-redundant functions of EMT transcription factors
Stemmler, M. P., Eccles, R. L., Brabletz, S., & Brabletz, T. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0196-y · Cited by 524
Self-citationKurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
YAP/TAZ Signaling and Resistance to Cancer Therapy
Nguyen, C. D. K., & Yi, C. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.010 · Cited by 437
Zinc finger proteins in cancer progression
Jen, J., & Wang, Y.-C. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0269-9 · Cited by 412
Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas
Jolly, M. K., Somarelli, J. A., Sheth, M., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S. M., Bapat, S. A., Rangarajan, A., & Levine, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.007 · Cited by 333
Analysis of the role of the Hippo pathway in cancer
Han, Y. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1869-4 · Cited by 287
YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer
Noguchi, S., Saito, A., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113674 · Cited by 277
Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity
Skrypek, N., Goossens, S., De Smedt, E., Vandamme, N., & Berx, G. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.08.004 · Cited by 271
Regulation of TEAD Transcription Factors in Cancer Biology
Huh, H., Kim, D., Jeong, H.-S., & Park, H. (2019) · Cells · doi:10.3390/cells8060600 · Cited by 259
The multiverse nature of epithelial to mesenchymal transition
Simeone, P., Trerotola, M., Franck, J., Cardon, T., Marchisio, M., Fournier, I., Salzet, M., Maffia, M., & Vergara, D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.11.004 · Cited by 98
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
Epithelial‐to‐mesenchymal transition transcription factors in cancer‐associated fibroblasts
Baulida, J. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12080 · Cited by 78
YAP/TAZ signalling in colorectal cancer: lessons from consensus molecular subtypes
Mouillet-Richard, S., & Laurent-Puig, P. (2020) · Cancers · doi:10.3390/cancers12113160 · Cited by 40
Metadata
- Authors
- Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., Herr, R., Brabletz, S., Stemmler, M. P., & Brabletz, T.
- Venue
- Nature Communications
- Published
- 2016-02-15
- Volume
- 7
- Issue
- 1
- Pages
- 10498-10498
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2323621372
- Cited by
- 305
- References
- 66
- FWCI
- 20.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.